{"id":143530,"date":"2022-05-27T14:50:49","date_gmt":"2022-05-27T12:50:49","guid":{"rendered":"https:\/\/medios.uchceu.es\/actualidad-ceu\/?p=143530"},"modified":"2022-05-30T16:45:16","modified_gmt":"2022-05-30T14:45:16","slug":"new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa","status":"publish","type":"post","link":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/","title":{"rendered":"New progesterone-based formulations show promise for the treatment of retinitis pigmentosa"},"content":{"rendered":"\n

Dr Adri\u00e1n Alambiaga, a member of the Drug Delivery Systems research group at CEU UCH<\/a>, led by Professor Alicia L\u00f3pez Castellano, studied the use of progesterone to treat retinitis pigmentosa for his doctoral thesis. When applied topically to the eye, this hormone can relieve oxidative stress on the retina, potentially slowing the degenerative course of the disease<\/strong><\/p>\n\n\n\n

\"\"
The research Dr Alambiaga undertook for his PhD at CEU UCH has already been published in high-impact journals.<\/figcaption><\/figure>\n\n\n\n

Retinitis pigmentosa <\/strong>is a degenerative disease affecting the photoreceptor cells in the retina, known as cones and rods. Of genetic origin, this disease first affects vision in low light conditions, and progressively peripheral vision and the central field of vision until total sight loss occurs, as the photoreceptor cells gradually die. Noting recent research into the role of hormones, particularly progesterone<\/strong>, in preventing cell death due to oxidative stress, the CEU UCH Drug Delivery Systems<\/u>(DDS)<\/a><\/strong> research group has successfully developed and tested a range of methods of delivery of this hormone into the eye<\/strong> to slow the degenerative process characteristic of retinitis pigmentosa.<\/p>\n\n\n\n

The research undertaken by the team is detailed in Dr Adri\u00e1n Alambiaga\u2019s doctoral thesis, supervised by Professor <\/u>Alicia L\u00f3pez Castellano<\/a> and Dr <\/u>Aracely Calatayud<\/a><\/strong>, and which he successfully defended at CEU in April. His findings, already published in several journals, show that progesterone can be delivered in various forms, such as eyedrops, micelles and inserts, in sufficient quantity to penetrate the surface of the eye and reach the neuroretina without causing significant toxicity or irritation. As Dr Adri\u00e1n Alambiaga told us, \u201cthe use of ocular inserts enables progesterone to be delivered in greater quantities than when aqueous solutions are used. Although we saw that aqueous solutions can also permeate the sclera and the cornea, inserts performed best in our tests, as they liberate progesterone for absorption by the neuroretina over a sustained period and in greater quantity.\u201d<\/p>\n\n\n\n

\"Adri\u00e1n
Dr Adri\u00e1n Alambiaga, together with his PhD supervisors, Professor Alicia L\u00f3pez Castellano and Dr Aracely Calatayud.<\/figcaption><\/figure>\n\n\n\n

Topical administration – the best option<\/strong><\/p>\n\n\n\n

Progesterone is virtually insoluble in water and it only dissolves in gastrointestinal fluids slowly and incompletely. This means that when it is administered orally, it quickly becomes ineffective. In addition, high levels of progesterone need to be administered orally so that just a small amount can reach the eye. \u201cThat\u2019s why it was important to study the different ways of administering progesterone topically or locally in the eye<\/strong>, thereby limiting the amount that has to be administered.\u201d<\/p>\n\n\n\n

Over the course of his doctoral research, Dr Alambiaga, under the supervision of Prof L\u00f3pez Castellano and Dr Calatayud, developed a range of pharmaceutical formulations of progesterone for topical delivery to the eye<\/strong>. These included aqueous solutions, which increase the durability and diffusion of the molecules on the ocular surface, and ocular inserts, which increase the contact time of the drug on the ocular surface, increase drug availability to the body, and enable a controlled release, more precise dosages and less frequent administration.<\/p>\n\n\n\n

\"\"
The members of the Drug Delivery Systems (DDS) research group at the CEU Cardenal Herrera University (CEU UCH), with Dr Adri\u00e1n Alambiaga and Professor Alicia L\u00f3pez Castellano in the centre-left.<\/figcaption><\/figure>\n\n\n\n

New treatment strategies<\/strong><\/p>\n\n\n\n

For the group\u2019s lead researcher, Professor Alicia L\u00f3pez Castellano<\/a><\/strong><\/u><\/strong>, who specialises in pharmaceutical technology at CEU UCH, Dr Alambiaga\u2019s thesis <\/strong>shows that \u201cwe have demonstrated for the first time that topical administration of progesterone in the eye is viable<\/strong>. This opens up possible new therapeutic strategies for retinitis pigmentosa patients, and by extension for patients with other eye conditions in which oxidative stress is a risk factor, such as glaucoma, age-related macular degeneration, macular oedema due to retinal vein occlusion, cytomegalovirus retinitis, posterior uveitis and diabetic retinopathy.\u201d<\/p>\n\n\n\n

Parts of Dr Adri\u00e1n Alambiaga\u2019s thesis have been published as research articles in journals <\/strong>such as Pharmaceutics<\/em>, the Journal of Pharmaceuticals and Biomedical Analysis<\/em>, and the International Journal of Pharmaceutics<\/em>.<\/p>\n\n\n\n

These articles are available here:<\/strong><\/p>\n\n\n\n

Micelles of Progesterone for Topical Eye Administration: Interspecies and Intertissues Differences in Ex Vivo Ocular Permeability.<\/a><\/p>\n\n\n\n

Alambiaga-Caravaca AM, Calatayud-Pascual MA, Rodilla V, Concheiro A, L\u00f3pez-Castellano A, Alvarez-Lorenzo C. Pharmaceutics<\/em>. 2020 Jul 26;12(8):702. doi: 10.3390\/pharmaceutics12080702.<\/p>\n\n\n\n

HPLC-UV analytical validation of a method for quantification of progesterone in ex vivo trans-corneal and trans-scleral diffusion studies.<\/a><\/p>\n\n\n\n

Alambiaga-Caravaca AM, Domenech-Monsell IM, Sebasti\u00e1n-Morell\u00f3 M, Miranda M, Balaguer-Fern\u00e1ndez C, Calatayud-Pascual A, Rodilla V, L\u00f3pez-Castellano A. J Pharm Biomed Anal<\/em>. 2021 Jan 30;193:113749. doi: 10.1016\/j.jpba.2020.113749. Epub 2020 Nov 6.<\/p>\n\n\n\n

Development, characterization, and ex vivo evaluation of an insert for the ocular administration of progesterone.<\/a><\/p>\n\n\n\n

Alambiaga-Caravaca AM, Domenech-Monsell IM, Sebasti\u00e1n-Morell\u00f3 M, Calatayud-Pascual MA, Merino V, Rodilla V, L\u00f3pez-Castellano A. Int J Pharm. 2021 Sep 5;606:120921. doi: 10.1016\/j.ijpharm.2021.120921. Epub 2021 Jul 23.<\/p>\n\n\n\n

Topical ocular administration of progesterone decreases photoreceptor cell death in retinal degeneration slow (rds) mice<\/a>. <\/p>\n\n\n\n

Alambiaga-Caravaca AM, Cant\u00f3 A, Rodilla V, Miranda M, L\u00f3pez-Castellano A. Pharmaceuticals<\/em>. 2022 15 <\/em>(3), 328; https:\/\/doi.org\/10.3390\/ph15030328<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Dr Adri\u00e1n Alambiaga, a member of the Drug Delivery Systems research group at CEU UCH, led by Professor Alicia L\u00f3pez Castellano, studied the use of progesterone to treat retinitis pigmentosa for his doctoral thesis. When applied topically to the eye, this hormone can relieve oxidative stress on the retina, potentially slowing the degenerative course of […]<\/p>\n","protected":false},"author":7,"featured_media":142362,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","footnotes":""},"categories":[3,4,1414,1090],"tags":[178,1671],"class_list":["post-143530","post","type-post","status-publish","format-standard","has-post-thumbnail","category-actualidad-cientifica","category-ciencias-de-la-salud-actualidad-cientifica","category-uncategorized","category-destacada_home2","tag-facultad-ciencias-de-la-salud","tag-scientific-papers"],"yoast_head":"\nNew progesterone-based formulations show promise for the treatment of retinitis pigmentosa<\/title>\n<meta name=\"description\" content=\"Dr Adri\u00e1n Alambiaga, a member of the Drug Delivery Systems research group at CEU UCH, led by Professor Alicia L\u00f3pez Castellano, studied the use of progesterone to treat retinitis pigmentosa for his doctoral thesis. When applied topically to the eye, this hormone can relieve oxidative stress on the retina, potentially slowing the degenerative course of the disease\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New progesterone-based formulations show promise for the treatment of retinitis pigmentosa\" \/>\n<meta property=\"og:description\" content=\"Dr Adri\u00e1n Alambiaga, a member of the Drug Delivery Systems research group at CEU UCH, led by Professor Alicia L\u00f3pez Castellano, studied the use of progesterone to treat retinitis pigmentosa for his doctoral thesis. When applied topically to the eye, this hormone can relieve oxidative stress on the retina, potentially slowing the degenerative course of the disease\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Actualidad CEU\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UCHCEU\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-27T12:50:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-30T14:45:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1990\" \/>\n\t<meta property=\"og:image:height\" content=\"1326\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Elisa Marco\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@uchceu\" \/>\n<meta name=\"twitter:site\" content=\"@uchceu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Elisa Marco\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\\\/\"},\"author\":{\"name\":\"Elisa Marco\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/#\\\/schema\\\/person\\\/31ddba919ce9f30ec285d011f857b334\"},\"headline\":\"New progesterone-based formulations show promise for the treatment of retinitis pigmentosa\",\"datePublished\":\"2022-05-27T12:50:49+00:00\",\"dateModified\":\"2022-05-30T14:45:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\\\/\"},\"wordCount\":846,\"publisher\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/05\\\/tesis-adrian-alambiaga-grupo.jpg\",\"keywords\":[\"Facultad Ciencias de la Salud\",\"Scientific Papers\"],\"articleSection\":{\"0\":\"Actualidad Cient\u00edfica\",\"1\":\"Ciencias de la Salud\",\"3\":\"xSegunda noticia en home\"},\"inLanguage\":\"en-US\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\\\/\",\"url\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\\\/\",\"name\":\"New progesterone-based formulations show promise for the treatment of retinitis pigmentosa\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/05\\\/tesis-adrian-alambiaga-grupo.jpg\",\"datePublished\":\"2022-05-27T12:50:49+00:00\",\"dateModified\":\"2022-05-30T14:45:16+00:00\",\"description\":\"Dr Adri\u00e1n Alambiaga, a member of the Drug Delivery Systems research group at CEU UCH, led by Professor Alicia L\u00f3pez Castellano, studied the use of progesterone to treat retinitis pigmentosa for his doctoral thesis. When applied topically to the eye, this hormone can relieve oxidative stress on the retina, potentially slowing the degenerative course of the disease\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/05\\\/tesis-adrian-alambiaga-grupo.jpg\",\"contentUrl\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/05\\\/tesis-adrian-alambiaga-grupo.jpg\",\"width\":1990,\"height\":1326},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New progesterone-based formulations show promise for the treatment of retinitis pigmentosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/\",\"name\":\"Actualidad CEU\",\"description\":\"El peri\u00f3dico de la Universidad CEU Cardenal Herrera\",\"publisher\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/#organization\"},\"alternateName\":\"AC\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/#organization\",\"name\":\"Universidad CEU Cardenal Herrera\",\"url\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2018\\\/11\\\/logotipo-ceu-uch-gris.png\",\"contentUrl\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2018\\\/11\\\/logotipo-ceu-uch-gris.png\",\"width\":540,\"height\":140,\"caption\":\"Universidad CEU Cardenal Herrera\"},\"image\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/UCHCEU\",\"https:\\\/\\\/x.com\\\/uchceu\",\"https:\\\/\\\/www.instagram.com\\\/uchceu_universidad\",\"https:\\\/\\\/www.linkedin.com\\\/school\\\/497316\",\"https:\\\/\\\/www.youtube.com\\\/ceuvalencia\",\"https:\\\/\\\/www.tiktok.com\\\/@uchceu_universidad\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/#\\\/schema\\\/person\\\/31ddba919ce9f30ec285d011f857b334\",\"name\":\"Elisa Marco\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed64f0e17f4cceecb56f2f81d2a17bcf0f0e787a2c7abf00b5aeea711849fd16?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed64f0e17f4cceecb56f2f81d2a17bcf0f0e787a2c7abf00b5aeea711849fd16?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed64f0e17f4cceecb56f2f81d2a17bcf0f0e787a2c7abf00b5aeea711849fd16?s=96&d=mm&r=g\",\"caption\":\"Elisa Marco\"},\"url\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/en\\\/author\\\/elisa\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New progesterone-based formulations show promise for the treatment of retinitis pigmentosa","description":"Dr Adri\u00e1n Alambiaga, a member of the Drug Delivery Systems research group at CEU UCH, led by Professor Alicia L\u00f3pez Castellano, studied the use of progesterone to treat retinitis pigmentosa for his doctoral thesis. When applied topically to the eye, this hormone can relieve oxidative stress on the retina, potentially slowing the degenerative course of the disease","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/","og_locale":"en_US","og_type":"article","og_title":"New progesterone-based formulations show promise for the treatment of retinitis pigmentosa","og_description":"Dr Adri\u00e1n Alambiaga, a member of the Drug Delivery Systems research group at CEU UCH, led by Professor Alicia L\u00f3pez Castellano, studied the use of progesterone to treat retinitis pigmentosa for his doctoral thesis. When applied topically to the eye, this hormone can relieve oxidative stress on the retina, potentially slowing the degenerative course of the disease","og_url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/","og_site_name":"Actualidad CEU","article_publisher":"https:\/\/www.facebook.com\/UCHCEU","article_published_time":"2022-05-27T12:50:49+00:00","article_modified_time":"2022-05-30T14:45:16+00:00","og_image":[{"width":1990,"height":1326,"url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo.jpg","type":"image\/jpeg"}],"author":"Elisa Marco","twitter_card":"summary_large_image","twitter_creator":"@uchceu","twitter_site":"@uchceu","twitter_misc":{"Written by":"Elisa Marco","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/#article","isPartOf":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/"},"author":{"name":"Elisa Marco","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/#\/schema\/person\/31ddba919ce9f30ec285d011f857b334"},"headline":"New progesterone-based formulations show promise for the treatment of retinitis pigmentosa","datePublished":"2022-05-27T12:50:49+00:00","dateModified":"2022-05-30T14:45:16+00:00","mainEntityOfPage":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/"},"wordCount":846,"publisher":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/#organization"},"image":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo.jpg","keywords":["Facultad Ciencias de la Salud","Scientific Papers"],"articleSection":{"0":"Actualidad Cient\u00edfica","1":"Ciencias de la Salud","3":"xSegunda noticia en home"},"inLanguage":"en-US"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/","url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/","name":"New progesterone-based formulations show promise for the treatment of retinitis pigmentosa","isPartOf":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/#primaryimage"},"image":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo.jpg","datePublished":"2022-05-27T12:50:49+00:00","dateModified":"2022-05-30T14:45:16+00:00","description":"Dr Adri\u00e1n Alambiaga, a member of the Drug Delivery Systems research group at CEU UCH, led by Professor Alicia L\u00f3pez Castellano, studied the use of progesterone to treat retinitis pigmentosa for his doctoral thesis. When applied topically to the eye, this hormone can relieve oxidative stress on the retina, potentially slowing the degenerative course of the disease","breadcrumb":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/#primaryimage","url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo.jpg","contentUrl":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo.jpg","width":1990,"height":1326},{"@type":"BreadcrumbList","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/new-progesterone-based-formulations-show-promise-for-the-treatment-of-retinitis-pigmentosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/"},{"@type":"ListItem","position":2,"name":"New progesterone-based formulations show promise for the treatment of retinitis pigmentosa"}]},{"@type":"WebSite","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/#website","url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/","name":"Actualidad CEU","description":"El peri\u00f3dico de la Universidad CEU Cardenal Herrera","publisher":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/#organization"},"alternateName":"AC","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/#organization","name":"Universidad CEU Cardenal Herrera","url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/#\/schema\/logo\/image\/","url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2018\/11\/logotipo-ceu-uch-gris.png","contentUrl":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2018\/11\/logotipo-ceu-uch-gris.png","width":540,"height":140,"caption":"Universidad CEU Cardenal Herrera"},"image":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UCHCEU","https:\/\/x.com\/uchceu","https:\/\/www.instagram.com\/uchceu_universidad","https:\/\/www.linkedin.com\/school\/497316","https:\/\/www.youtube.com\/ceuvalencia","https:\/\/www.tiktok.com\/@uchceu_universidad"]},{"@type":"Person","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/#\/schema\/person\/31ddba919ce9f30ec285d011f857b334","name":"Elisa Marco","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/ed64f0e17f4cceecb56f2f81d2a17bcf0f0e787a2c7abf00b5aeea711849fd16?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ed64f0e17f4cceecb56f2f81d2a17bcf0f0e787a2c7abf00b5aeea711849fd16?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ed64f0e17f4cceecb56f2f81d2a17bcf0f0e787a2c7abf00b5aeea711849fd16?s=96&d=mm&r=g","caption":"Elisa Marco"},"url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/author\/elisa\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo.jpg",1990,1326,false],"thumbnail":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-150x150.jpg",150,150,true],"medium":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-300x200.jpg",300,200,true],"medium_large":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-768x512.jpg",696,464,true],"large":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-1060x706.jpg",696,464,true],"listado":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-310x174.jpg",310,174,true],"nuevaweb":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-280x280.jpg",280,280,true],"destacadablogs":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-580x280.jpg",580,280,true],"1536x1536":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-1536x1023.jpg",1536,1023,true],"2048x2048":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo.jpg",1990,1326,false],"complete_open_graph":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-1200x800.jpg",1200,800,true],"td_150x0":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-150x100.jpg",150,100,true],"td_218x150":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-218x150.jpg",218,150,true],"td_300x0":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-300x200.jpg",300,200,true],"td_324x400":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-324x400.jpg",324,400,true],"td_485x360":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-485x360.jpg",485,360,true],"td_696x0":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-696x464.jpg",696,464,true],"td_1068x0":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-1068x712.jpg",1068,712,true],"td_1920x0":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-1920x1279.jpg",1920,1279,true],"td_0x420":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-630x420.jpg",630,420,true],"td_80x60":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-80x60.jpg",80,60,true],"td_100x70":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-100x70.jpg",100,70,true],"td_265x198":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-265x198.jpg",265,198,true],"td_324x160":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-324x160.jpg",324,160,true],"td_324x235":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-324x235.jpg",324,235,true],"td_356x220":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-356x220.jpg",356,220,true],"td_356x364":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-356x364.jpg",356,364,true],"td_533x261":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-533x261.jpg",533,261,true],"td_534x462":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-534x462.jpg",534,462,true],"td_696x385":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-696x385.jpg",696,385,true],"td_741x486":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-741x486.jpg",741,486,true],"td_1068x580":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2022\/05\/tesis-adrian-alambiaga-grupo-1068x580.jpg",1068,580,true]},"uagb_author_info":{"display_name":"Elisa Marco","author_link":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/author\/elisa\/"},"uagb_comment_info":0,"uagb_excerpt":"Dr Adri\u00e1n Alambiaga, a member of the Drug Delivery Systems research group at CEU UCH, led by Professor Alicia L\u00f3pez Castellano, studied the use of progesterone to treat retinitis pigmentosa for his doctoral thesis. When applied topically to the eye, this hormone can relieve oxidative stress on the retina, potentially slowing the degenerative course of…","_links":{"self":[{"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/wp-json\/wp\/v2\/posts\/143530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/wp-json\/wp\/v2\/comments?post=143530"}],"version-history":[{"count":3,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/wp-json\/wp\/v2\/posts\/143530\/revisions"}],"predecessor-version":[{"id":143533,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/wp-json\/wp\/v2\/posts\/143530\/revisions\/143533"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/wp-json\/wp\/v2\/media\/142362"}],"wp:attachment":[{"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/wp-json\/wp\/v2\/media?parent=143530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/wp-json\/wp\/v2\/categories?post=143530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/en\/wp-json\/wp\/v2\/tags?post=143530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}